Physician

Meghana Raghavendra, MD

According to 2025 Medicare claims, Meghana Raghavendra, MD (NPI: 1902916109) practices hematology/oncology in the Columbus, IN market, with the plurality of this provider's patient population coming from Bartholomew, IN. This provider's primary affiliated billing organization is FRANCISCAN PHYSICIAN NETWORK (NPI: 1225327984; TIN: 611630276) and primary practice location at 47201-6705. Raghavendra is affiliated with the Franciscan ACO, Inc. (ACO ID: A2550), participating under the MSSP model.

Raghavendra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 538 traditional Medicare patients, billed 12,692 HCPCS/CPT codes, and received $310,764 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,601 prescription claims across 347 beneficiaries totaling $3,629,928 in drug costs, led by Revlimid (Lenalidomide). DME data shows 48 claims. Open Payments data shows 15 records totaling $34,660. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $228,602 to $310,764. In contrast, Part D prescription costs have risen steadily, from $290,765 to $3,629,928. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $1,984 and ending at $1,967.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	228	9,576	$228,602
2016	293	36,895	$557,426
2017	298	70,619	$710,378
2018	460	72,942	$1,114,088
2019	609	75,162	$1,417,671
2020	472	70,496	$1,336,837
2021	490	28,263	$665,450
2022	503	13,663	$424,499
2023	560	16,164	$390,726
2024	538	12,692	$310,764

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	82	466	$290,765
2016	118	1,010	$583,951
2017	140	1,083	$840,096
2018	206	1,491	$1,713,385
2019	264	1,686	$2,108,787
2020	230	1,374	$2,109,591
2021	235	1,203	$2,511,201
2022	264	1,498	$2,863,638
2023	318	1,535	$2,420,523
2024	347	1,601	$3,629,928

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	96	$7,159
2017	N/R	100	$8,716
2018	N/R	40	$1,511
2019	N/R	53	$6,590
2020	N/R	125	$9,637
2021	N/R	122	$8,252
2022	N/R	39	$1,805
2023	N/R	49	$1,084
2024	N/R	48	$1,878

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	62	62	$143
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	96	218	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	224	478	$77
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	331	437	$53
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	61	61	$28

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	28	793	$474,922
Lumakras	Sotorasib	19	570	$394,655
Xtandi	Enzalutamide	26	780	$389,606
Imbruvica	Ibrutinib	24	694	$340,646
Jakafi	Ruxolitinib Phosphate	18	540	$339,775

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	17	$1,345
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$201	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$34,459	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Meghana Raghavendra, MD?

Tedicare shows public-source Medicare data for Meghana Raghavendra, MD (NPI 1902916109), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Meghana Raghavendra, MD have ACO affiliation data?

Meghana Raghavendra, MD is shown with ACO affiliation data for Franciscan ACO, Inc. (MSSP, ACO ID A2550).

What billing organization is linked to Meghana Raghavendra, MD?

Meghana Raghavendra, MD is linked to FRANCISCAN PHYSICIAN NETWORK (billing NPI 1225327984) in the available physician profile data.

Does Meghana Raghavendra, MD have Open Payments data?

Meghana Raghavendra, MD has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.